• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Galapagos

A ballpoint pen rests on top of a stack of documents ready for signing
Biotech

Rebranded Galapagos finally finds buyer for cell therapies

Lakefront Biotherapeutics—the new name for Belgium’s Galapagos Therapeutics—has found a buyer for its unwanted cell therapy pipeline.
James Waldron Oct 15, 2026 4:09am
Uninhabited island full of trees

Rebranded biotech lands $125M for rescued Galapagos assets

Apr 28, 2026 7:00am
Gilead and Kites exhibit booth at ASH 2025

Gilead's $2.2B Ouro buy delivers TCE, new purpose for Galapagos

Mar 24, 2026 3:34am
Euros cash money

Galapagos took €228M hit from cell therapy wind-down

Feb 24, 2026 6:30am
Comedy and tragedy masks on red curtain background

Galapagos' last immunology asset posts mixed results

Dec 19, 2025 6:05am
topic report
Rotten tomato splat fruit

Fierce Biotech's Rotten Tomatoes of 2025

Dec 16, 2025 4:30am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings